Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Halozyme (HALO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$130.34+1.34%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
10.30 → 10.42 EPS · FY ending Dec 31, 2027 · 4 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 4 to 4; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for HALO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash from operations growth to support investments | Cash from operations strengthens to $180M, supporting growth and investments. | Improving | Cash from operations falls below $180M in FY26 | Cash from operations: $240.891M FY2026-Q2; GAAP. Published target: Sustain or grow cash from operations above $180M through FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026240,891,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-oriented healthcare business with strong recent financial performance and a favorable sector backdrop. The long-term thesis is intact, but management execution has been volatile and the evidence snapshot gives medium confidence.
The valuation is described as justified, with no fragility warning, and the model places HALO at a premium to peers. Expectations appear broadly aligned with the evidence, though the reported expectations-gap measure is negative; the snapshot does not explain its scale or meaning in plain terms.
Near-term fundamentals have strong support: second-quarter 2026 revenue and royalty revenue grew 48% and 50% year over year, and management has repeatedly raised guidance. Share repurchases are also underway, while acquisitions are expanding the delivery-technology portfolio and adding to research and amortization costs. The next report remains a watch point because recent quarters have had misses, and reversing recently raised guidance would damage credibility.
The multi-year thesis depends on continued revenue growth and management delivering on guidance while integrating its acquisitions. Near-term risk rises if guidance is cut or employment data weakens further, which could weigh on healthcare names. Continued earnings strength and higher guidance from sector peers would support the sector backdrop.
Over the next 1 to 3 years, HALO’s strong growth and sector support keep the long-term thesis intact, but execution, guidance credibility, and acquisition costs warrant attention. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stable management execution despite COO departure |
| A supporting condition in Halozyme's published investment case. The stated target is Maintain stable execution and meet guidance in next quarters. |
| Improving |
| Further key management departures or failure to meet guidance |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improvement to support profit growth | Profit improves with operating income rising to $184M by Q1 2026. | Improving | Operating income growth stalls or declines below prior trend in FY26 | Operating income: $287.654M FY2026-Q2; GAAP. Published target: Operating income growth consistent with prior trend through FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026287,654,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “• Adjusted EBITDA of $1.225 billion to $1.280 billion, representing growth of 86% to 95% over 2025, including new Hypercon™ and Surf Bio investments of approximately $60 million.” “• Adjusted EBITDA of $1.125 billion to $1.205 billion, representing growth of 71% to 83% over 2025, including new Hypercon™ and Surf Bio investment of approximately $60 million.” Operating income was $287.654 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Annual revenue growth reaching ~21% in FY26 | A primary condition in Halozyme's published investment case. The stated target is >=20.9% YoY revenue growth. | Intact | YoY revenue growth falls below ~20.9% in FY26 | Revenue growth: 47.67% FY2026-Q2; GAAP. Published target: >=20.9% YoY revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 202647.672994 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “For the full year 2026, the Company expects: • Total revenue of $1.835 billion to $1.910 billion, representing growth of 31% to 37% over 2025 total revenue, primarily driven by increases in royalty revenue and product sales from API.” “• Revenue from royalties of $1.220 billion to $1.245 billion, representing growth of 41% to 43% over 2025.” Revenue was $480.999 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$9.98 → $10.42 · observed estimates
$2.01B → $2.10B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $9.98 | $2,005,636,237 | 4 / 7 |
| 2026-07-25 | $9.99 | $2,004,518,290 | 5 / 8 |
| 2026-07-26 | $9.99 | $2,004,518,290 | 5 / 8 |
| 2026-07-27 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-07-28 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-07-29 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-07-30 | $9.99 | $2,004,518,290 | 5 / 8 |
| 2026-07-31 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-08-01 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-08-02 | $9.99 | $2,004,518,290 | 5 / 8 |
| 2026-08-03 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-08-04 | $9.99 | $2,004,518,290 | 5 / 8 |
| 2026-08-05 | $9.99 | $2,004,518,290 | 5 / 8 |
| 2026-08-06 | $9.99 | $2,004,518,290 | 5 / 8 |
| 2026-08-07 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-08-08 | $10.19 | $2,030,331,910 | 5 / 8 |
| 2026-08-09 | $10.19 | $2,030,331,910 | 5 / 8 |
| 2026-08-10 | $10.19 | $2,030,331,910 | 5 / 8 |
| 2026-08-12 | $10.39 | $2,050,671,910 | 5 / 8 |
| 2026-08-13 | $10.39 | $2,050,671,910 | 5 / 8 |
| 2026-08-14 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-08-15 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-08-16 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-08-17 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-08-18 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-08-19 | $9.97 | $2,004,526,867 | 4 / 6 |
| 2026-08-20 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-21 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-22 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-23 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-24 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-25 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-26 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-27 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-28 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-29 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-30 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-08-31 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-09-01 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-09-02 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-09-03 | $10.31 | $2,050,680,490 | 4 / 6 |
| 2026-09-04 | $10.30 | $2,050,667,027 | 4 / 6 |
| 2026-09-05 | $10.30 | $2,050,667,027 | 4 / 6 |
| 2026-09-06 | $10.30 | $2,050,667,027 | 4 / 6 |
| 2026-09-07 | $10.30 | $2,050,667,027 | 4 / 6 |
| 2026-09-08 | $10.30 | $2,050,667,027 | 4 / 6 |
| 2026-09-09 | $10.30 | $2,050,667,027 | 4 / 6 |
| 2026-09-10 | $10.30 | $2,050,667,027 | 4 / 6 |
| 2026-09-11 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-12 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-13 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-14 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-15 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-16 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-17 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-18 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-19 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-20 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-21 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-22 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-23 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-24 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-25 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-26 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-27 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-28 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-29 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-09-30 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-10-01 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-10-02 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-10-03 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-10-04 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-10-05 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-10-06 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-10-07 | $10.30 | $2,050,305,490 | 4 / 6 |
| 2026-10-08 | $10.30 | $2,050,667,027 | 4 / 6 |
| 2026-10-09 | $10.50 | $2,071,794,528 | 3 / 6 |
| 2026-10-10 | $10.50 | $2,071,794,528 | 3 / 6 |
| 2026-10-11 | $10.50 | $2,071,794,528 | 4 / 6 |
| 2026-10-12 | $10.50 | $2,071,794,528 | 4 / 6 |
| 2026-10-13 | $10.50 | $2,071,794,528 | 4 / 6 |
| 2026-10-14 | $10.37 | $2,090,042,027 | 4 / 6 |
| 2026-10-15 | $10.37 | $2,090,042,027 | 4 / 6 |
| 2026-10-16 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-17 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-18 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-19 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-20 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-21 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-22 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-23 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-24 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-25 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-26 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-27 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-28 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-29 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-30 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-10-31 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-11-01 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-11-02 | $10.41 | $2,100,667,027 | 4 / 6 |
| 2026-11-03 | $10.41 | $2,100,629,528 | 4 / 6 |
| 2026-11-04 | $10.42 | $2,102,254,528 | 4 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 4 recorded
1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.